Thomas Charles Merigan M.D.

Publications

• In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis. Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC. PLoS One. 2013; 8 (4): e61102
• Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance. Rath BA, Olshen RA, Halpern J, Merigan TC. Viruses. 2012; 4 (8): 1212-34
• Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Nat Med. 2009; 15 (3): 285-92
• Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB. J Acquir Immune Defic Syndr. 2006; 42 (4): 426-34
• Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Pharmacogenet Genomics. 2006; 16 (11): 837-45
• "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Structure. 2005; 13 (12): 1887-95
• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Clin Infect Dis. 2005; 41 (2): 236-42
• Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Winters MA, Merigan TC. Antimicrob Agents Chemother. 2005; 49 (7): 2575-82
• New two-amino acid insertion near codon 70 of the HIV type 1 protease gene. Winters MA, Kagan RM, Heseltine PN, Merigan TC. AIDS Res Hum Retroviruses. 2005; 21 (4): 311-3
• Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 2005; 39 (1): 78-81
• Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB. J Infect Dis. 2005; 192 (11): 1931-42
• Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD. Antimicrob Agents Chemother. 2005; 49 (8): 3558-61
• Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. Winters MA, Kagan RM, Kovari L, Heseltine PN, Merigan TC. Antivir Ther. 2005; 10 (2): 363-6
• Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Antimicrob Agents Chemother. 2004; 48 (12): 4864-8
• Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. J Virol. 2004; 78 (6): 3123-32
• HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. Kagan R, Winters M, Merigan T, Heseltine P. AIDS Res Hum Retroviruses. 2004; 20 (1): 1-9
• Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, Merigan TC. AIDS Res Hum Retroviruses. 2004; 20 (11): 1166-72
• Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Kagan RM, Merigan TC, Winters MA, Heseltine PN. Antivir Ther. 2004; 9 (5): 827-8
• Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. J Infect Dis. 2004; 189 (6): 1075-83
• Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. N Engl J Med. 2003; 349 (24): 2304-15
• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS. N Engl J Med. 2003; 349 (24): 2293-303
• Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan TC, Reichman RC, Berggren R, Burning WJ, Brobst S. J Acquir Immune Defic Syndr. 2003; 33 (3): 329-35
• Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ. J Infect Dis. 2003; 188 (12): 1804-14
• HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC. Protein Expr Purif. 2003; 28 (1): 165-72
• A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma. Qari SH, Winters M, Vandamme AM, Merigan T, Heneine W. Antivir Ther. 2002; 7 (2): 131-9
• Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL. AIDS. 2002; 16 (8): 1131-8
• Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. Lobato RL, Kim EY, Kagan RM, Merigan TC. AIDS Res Hum Retroviruses. 2002; 18 (10): 733-6
• Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. Kim EY, Vrang L, Oberg B, Merigan TC. AIDS Res Hum Retroviruses. 2001; 17 (5): 401-7
• Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). Kundu-Raychaudhuri S, Sevin A, Kilgo P, Nokta M, Pollard RB, Merigan TC. AIDS Res Hum Retroviruses. 2001; 17 (15): 1371-8
• Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. Kim EY, Winters MA, Kagan RM, Merigan TC. J Virol. 2001; 75 (22): 11227-33
• Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. Winters MA, Merigan TC. Antimicrob Agents Chemother. 2001; 45 (8): 2276-9
• In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC. Cell Transplant. 2000 May-Jun; 9 (3): 307-17
• A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. AIDS. 2000; 14 (9): F83-93
• Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Antivir Ther. 2000; 5 (1): 57-63
• Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. Winters MA, Coolley KL, Cheng P, Girard YA, Hamdan H, Kovari LC, Merigan TC. J Virol. 2000; 74 (22): 10707-13
• Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC. AIDS Res Hum Retroviruses. 2000; 16 (14): 1357-69
• Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. J Infect Dis. 2000; 182 (5): 1357-64
• Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. Kleim JP, Winters M, Dunkler A, Suarez JR, Riess G, Winkler I, Balzarini J, Oette D, Merigan TC. J Infect Dis. 1999; 179 (3): 709-13
• Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, Winters MA, Lawrence J, Merigan TC. AIDS. 1999; 13 (3): 359-65
• Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. J Infect Dis. 1999; 179 (6): 1356-64
• Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC. J Acquir Immune Defic Syndr. 1999; 22 (4): 341-7
• Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK, Davis MM, Merigan TC. J Immunol. 1999; 162 (3): 1780-8
• HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. Ann Intern Med. 1999; 131 (11): 813-21
• Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Palmer S, Shafer RW, Merigan TC. Antimicrob Agents Chemother. 1999; 43 (8): 2046-50
• Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW, Merigan TC, Schroeder JS. Circulation. 1999; 100 (1): 61-6
• Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC. J Infect Dis. 1999; 179 (1): 249-53
• Viral resistance testing: practical issues and future opportunities - interview with Thomas Merigan, M.D. Interview by John S. James. Merigan T, AIDS Treat News. 1999; (No 316): 1-6
• Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Peshwa MV, Benike C, Dupuis M, Kundu SK, Engleman EG, Merigan TC, van Schooten WC. Cell Transplant. 1998 Jan-Feb; 7 (1): 1-9
• A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC. J Clin Invest. 1998; 102 (10): 1769-75
• A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC. AIDS Res Hum Retroviruses. 1998; 14 (7): 551-60
• Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. Gray CM, Schapiro JM, Winters MA, Merigan TC. AIDS Res Hum Retroviruses. 1998; 14 (7): 561-9
• Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. Zipeto D, Hong C, Gerna G, Zavattoni M, Katzenstein D, Merigan TC, Rasmussen L. AIDS Res Hum Retroviruses. 1998; 14 (6): 533-6
• HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17 (3): 203-8
• Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. Winters MA, Schapiro JM, Lawrence J, Merigan TC. J Virol. 1998; 72 (6): 5303-6
• Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. Schapiro JM, Winters MA, Vierra M, Crawford S, Merigan TC. J Infect Dis. 1998; 177 (2): 477-80
• Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Shafer RW, Winters MA, Palmer S, Merigan TC. Ann Intern Med. 1998; 128 (11): 906-11
• Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, Merigan TC. AIDS Res Hum Retroviruses. 1998; 14 (18): 1669-78
• Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. Merigan TC, J Reprod Immunol. 1998; 41 (1-2): 177-85
• A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. Jellinger RM, Shafer RW, Merigan TC. J Infect Dis. 1997; 175 (3): 561-6
• Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. Dupuis M, Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WC, Merigan TC. AIDS Res Hum Retroviruses. 1997; 13 (1): 33-9
• Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. Shafer RW, Levee DJ, Winters MA, Richmond KL, Huang D, Merigan TC. J Clin Microbiol. 1997; 35 (2): 520-2
• Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. Rasmussen L, Hong C, Zipeto D, Morris S, Sherman D, Chou S, Miner R, Drew WL, Wolitz R, Dowling A, Warford A, Merigan TC. J Infect Dis. 1997; 175 (1): 179-84
• Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 15 (4): 269-74
• Heterogeneity of cytokine functions in HIV infection. Kundu SK, Merigan TC. Immunology. 1997; 91 (2): 234-8
• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Antimicrob Agents Chemother. 1997; 41 (4): 757-62
• Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. Rasmussen L, Zipeto D, Wolitz RA, Dowling A, Efron B, Merigan TC. J Infect Dis. 1997; 176 (5): 1146-55
• Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. J Virol. 1997; 71 (7): 5441-8
• A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, Merigan TC. J Infect Dis. 1996; 173 (6): 1336-46
• A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. N Engl J Med. 1996; 335 (15): 1081-90
• Clinical treatment. Cooper DA, Merigan TC. AIDS. 1996: 10 Suppl A S133-4
• Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR. Nat Med. 1996; 2 (7): 753-9
• Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Shafer RW, Winters MA, Iversen AK, Merigan TC. Antimicrob Agents Chemother. 1996; 40 (12): 2887-90
• Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T. J Infect Dis. 1996; 174 (4): 854-7
• Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection. Dwyer DE, Adelstein S, Cunningham AL, Merigan TC. Med J Aust. 1996; 164 (5): 301-3
• Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC. J Virol. 1996; 70 (2): 1086-90
• Multiple cerebral lesions complicating therapy with interleukin-2. Karp BI, Yang JC, Khorsand M, Wood R, Merigan TC. Neurology. 1996; 47 (2): 417-24
• Patient compliance and drug failure in protease inhibitor monotherapy. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. JAMA. 1996; 276 (24): 1955-6
• Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. J Infect Dis. 1996; 173 (4): 1005-8
• The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. Ann Intern Med. 1996; 124 (12): 1039-50
• The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. Merigan TC, Hirsch RL, Fisher AC, Meyerson LA, Goldstein G, Winters MA. AIDS. 1996; 10 (2): 159-65
• The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS. N Engl J Med. 1996; 335 (15): 1091-8
• Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L. N Engl J Med. 1996; 334 (16): 1011-7
• Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. Shafer RW, Winters MA, Jellinger RM, Merigan TC. J Infect Dis. 1996; 174 (2): 448-9
• A quarter-century of antiviral therapy. Merigan TC, N Engl J Med. 1995; 333 (25): 1704-5
• AIDS 1995. Clinical treatment: overview. Weber J, Merigan TC. AIDS. 1995: 9 Suppl A S181-2
• Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein. Dupuis M, Kundu SK, Merigan TC. J Immunol. 1995; 155 (4): 2232-9
• Clarification of a method to reverse transcribe human immunodeficiency virus RNA. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. J Infect Dis. 1995; 171 (4): 1072
• HIV virology for clinical trials. Shafer RW, Merigan TC. AIDS. 1995: 9 Suppl A S193-202
• Heterogeneity in long-term response to HIV-infected individuals to zidovudine and didanosine combination therapy. Merigan, T.C., Shafer R.W., Iverson A.K.N, Winters M.A., Katzenstein D.A., and the ACTG 143 Virology Team.. Journal of Infectious Diseases. 1995; (172): 70-78
• Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. Zipeto D, Morris S, Hong C, Dowling A, Wolitz R, Merigan TC, Rasmussen L. J Clin Microbiol. 1995; 33 (10): 2607-11
• Human cytomegalovirus DNA is present in CD45+ cells in semen from human immunodeficiency virus-infected patients. Rasmussen L, Morris S, Hamed K, Merigan TC. J Infect Dis. 1995; 171 (2): 432-6
• Individualization of therapy using viral markers. Merigan T, J Acquir Immune Defic Syndr Hum Retrovirol. 1995: 10 Suppl 1 S41-6
• New virologic tools for the design and analysis of clinical trials. Shafer RW, Merigan TC. J Infect Dis. 1995; 171 (5): 1325-8
• Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI. J Virol. 1995; 69 (9): 5743-53
• Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB. Transplantation. 1995; 60 (12): 1473-7
• Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. Rasmussen L, Morris S, Zipeto D, Fessel J, Wolitz R, Dowling A, Merigan TC. J Infect Dis. 1995; 171 (1): 177-82
• Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1. Shafer RW, Aguiniga E, Merigan TC. J Clin Microbiol. 1995; 33 (1): 212-4
• Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 (2): 150-6
• The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. Tierney M, Pottage J, Kessler H, Fischl M, Richman D, Merigan T, Powderly W, Smith S, Karim A, Sherman J. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 (5): 549-53
• Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC. J Infect Dis. 1994; 170 (3): 673-7
• Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. J Infect Dis. 1994; 170 (5): 1292-5
• Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Ann Intern Med. 1994; 121 (4): 263-8
• Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. Ho RJ, Burke RL, Merigan TC. Vaccine. 1994; 12 (3): 235-42
• Diurnal and short-term stability of HIV virus load as measured by gene amplification. Holodniy M, Mole L, Winters M, Merigan TC. J Acquir Immune Defic Syndr. 1994; 7 (4): 363-8
• Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC. J Infect Dis. 1994; 170 (4): 1009-13
• HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC. J Acquir Immune Defic Syndr. 1994; 7 (8): 832-8
• Human immunodeficiency virus envelope glycoproteins. Merigan TC, Kundu SK. J Acquir Immune Defic Syndr. 1994: 7 Suppl 1 S14-20
• Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. Ramachandran RV, Katzenstein D, Merigan TC. J Infect Dis. 1994; 170 (4): 1044-6
• Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. J Infect Dis. 1994; 169 (2): 416-9
• Relationship of HIV-1 provirus load, CD8+ CD11+ T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic offients. Kundu SK, Merigan TC. Immunology. 1994; 83 (1): 81-5
• Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. AIDS Clinical Trial Research Group 047. Liu M, Fahey JL, Aziz N, Cumberland WG, Skowron G, Merigan T. J Infect Dis. 1994; 170 (5): 1165-71
• 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Berger AR, Arezzo JC, Schaumburg HH, Skowron G, Merigan T, Bozzette S, Richman D, Soo W. Neurology. 1993; 43 (2): 358-62
• A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (3): 526-32
• Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, Fischl MA, Powderly WG, Gocke DJ, Richman DD, Pottage JC, Antoniskis D, McKinley GF, Hyslop NE, Ray G, Simon G, Reed N, LoFaro ML, Uttamchandani RB, Gelb LD, Sperber SJ, Murphy RL, Leedom JM, Grieco MH, Zachary J, Hirsch MS, Spector SA, Bigley J, Soo W, Merigan TC. Ann Intern Med. 1993; 118 (5): 321-30
• Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. Winters MA, Tan LB, Katzenstein DA, Merigan TC. J Clin Microbiol. 1993; 31 (11): 2960-6
• Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. Winters MA, Merigan TC. AIDS Res Hum Retroviruses. 1993; 9 (11): 1091-6
• Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (4): 798-802
• Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (4): 366-9
• Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect. Montoya JG, Wood R, Katzenstein D, Holodny M, Merigan TC. J Clin Microbiol. 1993; 31 (10): 2692-6
• Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. J Acquir Immune Defic Syndr. 1993; 6 (1): 56-60
• Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. Wood R, Dong H, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (3): 237-40
• Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. J Infect Dis. 1993; 167 (3): 519-25
• Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC. J Virol Methods. 1993; 41 (3): 297-310
• A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM. N Engl J Med. 1992; 326 (18): 1182-6
• CD8+ CD11+ suppressor cells in HIV-infected asymptomatic patients: effect on HIV-specific cytotoxicity. Kundu SK, Merigan TC. Viral Immunol. 1992; 5 (1): 15-25
• Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (1): 52-9
• Detection and quantification of gene amplification products by a nonisotopic automated system. Holodniy M, Winters MA, Merigan TC. Biotechniques. 1992; 12 (1): 36, 38-9
• Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Kundu SK, Katzenstein D, Moses LE, Merigan TC. Proc Natl Acad Sci U S A. 1992; 89 (23): 11204-8
• Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes. Kundu SK, Merigan TC. AIDS. 1992; 6 (7): 643-9
• Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. Ho RJ, Burke RL, Merigan TC. Vaccine. 1992; 10 (4): 209-13
• Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (2): 107-12
• Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. Winters MA, Holodniy M, Katzenstein DA, Merigan TC. PCR Methods Appl. 1992; 1 (4): 257-62
• Resistance to interferon-alpha in a mouse B-cell lymphoma involves DNA methylation. Reid TR, Merigan TC, Basham TY. J Interferon Res. 1992; 12 (2): 131-7
• Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control. Merigan TC, Katzenstein DA. Rev Infect Dis. 1991 Mar-Apr; 13 (2): 292-302
• Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. Davis BR, Schwartz DH, Marx JC, Johnson CE, Berry JM, Lyding J, Merigan TC, Zander A. J Virol. 1991; 65 (4): 1985-90
• Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC. J Infect Dis. 1991; 164 (5): 835-42
• Antiviral activity and dose optimum of recombinant macrophage colony-stimulating factor on herpes simplex genitalis in guinea pigs. Ho RJ, Chong KT, Merigan TC. J Immunol. 1991; 146 (10): 3578-82
• Cytomegalovirus-specific cell-mediated immune responses in heart and heart-lung transplant recipients are not predictive for the occurrence of symptomatic CMV disease or tissue rejection. van Tiel FH, Rasmussen L, Merigan TC. J Interferon Res. 1991; 11 (4): 221-9
• Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. J Infect Dis. 1991; 163 (4): 862-6
• Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1991; 164 (4): 769-72
• Human cytomegalovirus glycoprotein-receptor interactions. Rasmussen L, Resta S, Merigan T. Transplant Proc. 1991; 23 (3 Suppl 3): 60-3
• Inhibition of human immunodeficiency virus gene amplification by heparin. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. J Clin Microbiol. 1991; 29 (4): 676-9
• Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. Basham T, Holdener T, Merigan T. J Infect Dis. 1991; 163 (4): 869-72
• Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection. Kundu SK, Merigan TC. Immunology. 1991; 74 (4): 567-71
• Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Merigan TC, Amato DA, Balsley J, Power M, Price WA, Benoit S, Perez-Michael A, Brownstein A, Kramer AS, Brettler D. Blood. 1991; 78 (4): 900-6
• Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. J Clin Invest. 1991; 88 (5): 1755-9
• Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. Schwartz DH, Skowron G, Merigan TC. J Acquir Immune Defic Syndr. 1991; 4 (1): 11-23
• Treatment of AIDS with combinations of antiretroviral agents. Merigan TC, Am J Med. 1991; 90 (4A): 8S-17S
• Treatment of cytomegalovirus infection in the AIDS patient. Merigan TC, Transplant Proc. 1991; 23 (3 Suppl 3): 122-5
• Cytomegalovirus: where have we been and where are we going? Merigan TC, Resta S. Rev Infect Dis. 1990 Sep-Oct: 12 Suppl 7 S693-700
• Acute delta hepatitis during treatment with adenosine arabinoside monophosphate with resolution of the HBsAg carrier state. Garcia G, Smedile A, Bergmann KF, Gerin JL, Gregory PB, Merigan TC, Robinson WS. West J Med. 1990; 153 (1): 80-2
• Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Skowron G, Merigan TC. Am J Med. 1990; 88 (5B): 20S-23S
• Clinical trials of combination therapies for HIV infection. Discussion. McGowan J, Merigan T, Sherwin S. J Acquir Immune Defic Syndr. 1990: 3 Suppl 2 S108-10
• Interleukin-2 in the treatment of HIV disease. Schwartz DH, Merigan TC. Biotherapy. 1990; 2 (2): 119-36
• Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs. Ho RJ, Burke RL, Merigan TC. Antiviral Res. 1990; 13 (4): 187-99
• Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Ann Intern Med. 1990; 112 (4): 247-53
• Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Merigan TC, Skowron G. Am J Med. 1990; 88 (5B): 11S-15S
• You can teach an old dog new tricks. How AIDS trials are pioneering new strategies. Merigan TC, N Engl J Med. 1990; 323 (19): 1341-3
• Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. Basham T, Rios CD, Holdener T, Merigan TC. J Infect Dis. 1990; 161 (5): 1006-9
• Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. Portnoi D, Stall AM, Schwartz D, Merigan TC, Herzenberg LA, Basham T. J Immunol. 1990; 144 (5): 1705-10
• A personal view of efforts in treatment of human immunodeficiency virus infection in 1988. Merigan TC, J Infect Dis. 1989; 159 (3): 390-9
• Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. Ho RJ, Burke RL, Merigan TC. J Virol. 1989; 63 (7): 2951-8
• Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischl M, Schooley R, Hirsch M, Soo W, Pettinelli C. Ann Intern Med. 1989; 110 (3): 189-94
• Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma. Reid TR, Race ER, Wolff BH, Friedman RM, Merigan TC, Basham TY. Cancer Res. 1989; 49 (15): 4163-9
• Evaluation of the antiviral effect of rifabutin in AIDS-related complex. Torseth J, Bhatia G, Harkonen S, Child C, Skinner M, Robinson WS, Blaschke TF, Merigan TC. J Infect Dis. 1989; 159 (6): 1115-8
• Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus. Keay S, Merigan TC, Rasmussen L. Proc Natl Acad Sci U S A. 1989; 86 (24): 10100-3
• Pharmacokinetics of rifabutin. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, Blaschke TF. Antimicrob Agents Chemother. 1989; 33 (8): 1237-41
• The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Pachl C, Probert WS, Hermsen KM, Masiarz FR, Rasmussen L, Merigan TC, Spaete RR. Virology. 1989; 169 (2): 418-26
• Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R. Blood. 1989; 73 (3): 651-61
• Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Keay S, Petersen E, Icenogle T, Zeluff BJ, Samo T, Busch D, Newman CL, Buhles WC, Merigan TC. Rev Infect Dis. 1988 Jul-Aug: 10 Suppl 3 S563-72
• Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. Rasmussen L, Nelson M, Neff M, Merigan TC. Virology. 1988; 163 (2): 308-18
• Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas. Basham TY, Palladino MA, Badger CC, Bernstein ID, Levy R, Merigan TC. Cancer Res. 1988; 48 (15): 4196-200
• Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, Rasmussen L, Merigan TC, Pachl C. Virology. 1988; 167 (1): 207-25
• Human interferon as a therapeutic agent: a decade passes. Merigan TC, N Engl J Med. 1988; 318 (22): 1458-60
• Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. Torseth JW, Berman PW, Merigan TC. AIDS Res Hum Retroviruses. 1988; 4 (1): 23-30
• Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. Bissett J, Eisenberg M, Gregory P, Robinson WS, Merigan TC. J Infect Dis. 1988; 157 (5): 1076-80
• Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. Weinberg A, Merigan TC. J Immunol. 1988; 140 (1): 294-9
• Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action. Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC. J Immunol. 1988; 141 (8): 2855-60
• Syngeneic monoclonal anti-idiotype antibodies that bear the internal image of a human cytomegalovirus neutralization epitope. Keay S, Rasmussen L, Merigan TC. J Immunol. 1988; 140 (3): 944-8
• Topical interferon for treating condyloma acuminata in women. Keay S, Teng N, Eisenberg M, Story B, Sellers PW, Merigan TC. J Infect Dis. 1988; 158 (5): 934-9
• Viral diseases in developing countries. Merigan TC, APMIS Suppl. 1988: 3 26-9
• Assessment of the antigenic response in humans to a recombinant mutant interferon beta. Konrad MW, Childs AL, Merigan TC, Borden EC. J Clin Immunol. 1987; 7 (5): 365-75
• Beta interferon produced by keratinocytes in human cutaneous infection with herpes simplex virus. Torseth JW, Nickoloff BJ, Basham TY, Merigan TC. J Infect Dis. 1987; 155 (4): 641-8
• Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. Keay S, Bissett J, Merigan TC. J Infect Dis. 1987; 156 (6): 1016-21
• Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease? Merigan TC, J Interferon Res. 1987; 7 (5): 635-9
• Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses. Torseth JW, Cohen GH, Eisenberg RJ, Berman PW, Lasky LA, Cerini CP, Heilman CJ, Kerwar S, Merigan TC. J Virol. 1987; 61 (5): 1532-9
• Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs. Weinberg A, Konrad M, Merigan TC. J Virol. 1987; 61 (7): 2120-7
• Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. Weinberg A, Rasmussen L, Merigan TC. J Infect Dis. 1986; 154 (1): 134-40
• Cervical intraepithelial neoplasia treated by perilesional injection of interferon. Choo YC, Seto WH, Hsu C, Merigan TC, Tan YH, Ma HK, Ng MH. Br J Obstet Gynaecol. 1986; 93 (4): 372-9
• Human keratinocyte-lymphocyte reactions in vitro. Nickoloff BJ, Basham TY, Merigan TC, Torseth JW, Morhenn VB. J Invest Dermatol. 1986; 87 (1): 11-8
• Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection. Eisenberg M, Rosno S, Garcia G, Konrad MW, Gregory PB, Robinson WS, Merigan TC. Antimicrob Agents Chemother. 1986; 29 (1): 122-6
• Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection. Weinberg A, Basham TY, Merigan TC. J Immunol. 1986; 137 (10): 3310-7
• Significance of local gamma interferon in recurrent herpes simplex infection. Torseth JW, Merigan TC. J Infect Dis. 1986; 153 (5): 979-84
• Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC. J Immunol. 1986; 137 (9): 3019-24
• Preliminary observation of hepatitis B-associated membranous glomerulonephritis treated with leukocyte interferon. Garcia G, Scullard G, Smith C, Weissberg J, Alexander S, Robinson WS, Gregory P, Merigan TC. Hepatology. 1985 Mar-Apr; 5 (2): 317-20
• Cytomegalovirus infection and abnormal T-lymphocyte subset ratios in homosexual men. Drew WL, Mills J, Lèvy J, Dylewski J, Casavant C, Ammann AJ, Brodie H, Merigan T. Ann Intern Med. 1985; 103 (1): 61-3
• Evolution of recurrent herpes simplex lesions. An immunohistologic study. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. J Clin Invest. 1985; 75 (1): 226-33
• Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo. Rasmussen L, Mullenax J, Nelson M, Merigan TC. Virology. 1985; 145 (1): 186-90
• Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H. Cancer. 1985; 56 (6): 1305-10
• Immunological complications in multiple sclerosis patients receiving interferon. Rice GP, Woelfel EL, Talbot PJ, Braheny SL, Sipe JC, Knobler RL, Merigan TC, Oldstone MB. Ann Neurol. 1985; 18 (4): 439-42
• Immunomodulatory and antiproliferative effect of recombinant alpha, beta, and gamma interferons on cultured human malignant squamous cell lines, SCL-1 and SW-1271. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. J Invest Dermatol. 1985; 84 (6): 487-90
• Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. Cunningham AL, Nelson PA, Fathman CG, Merigan TC. J Gen Virol. 1985: 66 ( Pt 2) 249-58
• Intravaginal application of leukocyte interferon gel in the treatment of cervical intraepithelial neoplasia (CIN). Choo YC, Hsu C, Seto WH, Miller DG, Merigan TC, Ng MH, Ma HK. Arch Gynecol. 1985; 237 (1): 51-4
• Keratinocyte class II histocompatibility antigen expression. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. Br J Dermatol. 1985; 112 (3): 373-4
• Phase I evaluation of a synthetic mutant of beta-interferon. Hawkins M, Horning S, Konrad M, Anderson S, Sielaff K, Rosno S, Schiesel J, Davis T, DeMets D, Merigan T. Cancer Res. 1985; 45 (11 Pt 2): 5914-20
• Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. J Interferon Res. 1985; 5 (1): 23-32
• Role of macrophage D-region antigens and T-lymphocyte differentiation antigens in induction of gamma interferon. Cunningham AL, Basham TY, Para MF, Merigan TC. J Interferon Res. 1985; 5 (3): 477-91
• Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Panitch HS, Francis GS, Hooper CJ, Merigan TC, Johnson KP. Ann Neurol. 1985; 18 (4): 434-8
• Transfusion-acquired cytomegalovirus infection in cardiac surgery patients. Preiksaitis JK, Grumet FC, Smith WK, Merigan TC. J Med Virol. 1985; 15 (3): 283-90
• Treatment of nasopharyngeal carcinoma with human leukocyte interferon. Connors JM, Andiman WA, Howarth CB, Liu E, Merigan TC, Savage ME, Jacobs C. J Clin Oncol. 1985; 3 (6): 813-7
• Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. Rasmussen L, Mullenax J, Nelson R, Merigan TC. J Virol. 1985; 55 (2): 274-80
• Exfoliative cytology in the evaluation of interferon treatment of cervical intraepithelial neoplasia. Hsu C, Choo YC, Seto WH, Pang SW, Tan CY, Merigan TC, Ng MH. Acta Cytol. 1984 Mar-Apr; 28 (2): 111-7
• Alpha-interferon administration in cytomegalovirus retinitis. Chou SW, Dylewski JS, Gaynon MW, Egbert PR, Merigan TC. Antimicrob Agents Chemother. 1984; 25 (1): 25-8
• Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. Lab Invest. 1984; 51 (6): 697-701
• Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU. Am J Med. 1984; 77 (3): 427-32
• Comparison of antiviral activities of cloned and native human interferons against herpes simplex virus types 1 and 2 and human cytomegalovirus. Rasmussen LE, Chen PT, Merigan TC. Antimicrob Agents Chemother. 1984; 26 (4): 599-600
• DNA of 21 clinical cytomegalovirus strains detected by hybridization to cloned DNA fragments of laboratory strain AD-169. Chou SW, Roark L, Merigan TC. J Med Virol. 1984; 14 (3): 263-8
• Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon. Kamin-Lewis RM, Panitch HS, Merigan TC, Johnson KP. J Interferon Res. 1984; 4 (3): 423-32
• High-performance liquid chromatographic analysis of hypoxanthine arabinoside in plasma. Smith GA, Giacomini KM, Smith CT, Gregory PB, Robinson WS, Merigan TC, Blaschke TF. J Chromatogr. 1984; 307 (2): 410-5
• Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Merigan TC, Baer GM, Winkler WG, Bernard KW, Gibert CG, Chany C, Veronesi R. Ann Neurol. 1984; 16 (1): 82-7
• Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferons. Rasmussen L, Chen PT, Mullenax JG, Merigan TC. Antimicrob Agents Chemother. 1984; 26 (4): 441-5
• Interferon enhances antibody-dependent cellular cytotoxicity when suboptimal concentrations of antibody are used. Basham TY, Smith WK, Merigan TC. Cell Immunol. 1984; 88 (2): 393-400
• Large-scale serological screening for cytomegalovirus antibodies in homosexual males by enzyme-linked immunosorbent assay. Dylewski JS, Rasmussen L, Mills J, Merigan TC. J Clin Microbiol. 1984; 19 (2): 200-3
• Leu-3+ T cells produce gamma-interferon in patients with recurrent herpes labialis. Cunningham AL, Merigan TC. J Immunol. 1984; 132 (1): 197-202
• Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Rasmussen LE, Nelson RM, Kelsall DC, Merigan TC. Proc Natl Acad Sci U S A. 1984; 81 (3): 876-80
• Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. J Invest Dermatol. 1984; 83 (2): 88-90
• Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. Basham T, Smith W, Lanier L, Morhenn V, Merigan T. Hum Immunol. 1984; 10 (2): 83-93
• Survival in chronic hepatitis B. An analysis of 379 patients. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB. Ann Intern Med. 1984; 101 (5): 613-6
• What are we going to do about AIDS and HTLV-III/LAV infection? Merigan TC, N Engl J Med. 1984; 311 (20): 1311-3
• Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS. Dylewski J, Chou S, Merigan TC. N Engl J Med. 1983; 309 (8): 493
• Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. Smith CI, Weissberg J, Bernhardt L, Gregory PB, Robinson WS, Merigan TC. J Infect Dis. 1983; 148 (5): 907-13
• Growth regulation of melanoma cells by interferon and (2'-5')oligoadenylate synthetase. Creasey AA, Eppstein DA, Marsh YV, Khan Z, Merigan TC. Mol Cell Biol. 1983; 3 (5): 780-6
• Human interferon as a therapeutic agent--current status. Merigan TC, N Engl J Med. 1983; 308 (25): 1530-1
• Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. Preiksaitis JK, Rosno S, Grumet C, Merigan TC. J Infect Dis. 1983; 147 (6): 974-81
• Interferon prophylaxis against simian varicella in Erythrocebus patas monkeys. Arvin AM, Martin DP, Gard EA, Merigan TC. J Infect Dis. 1983; 147 (1): 149-54
• Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Rice GP, Casali P, Merigan TC, Oldstone MB. Ann Neurol. 1983; 14 (3): 333-8
• Phase I study of human leukocyte interferon in patients with advanced cancer. Horning SJ, Levine JF, Meyer M, Merigan TC, Rosenberg SA. J Biol Response Mod. 1983; 2 (1): 47-56
• Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. Chou S, Merigan TC. N Engl J Med. 1983; 308 (16): 921-5
• Recombinant interferon-gamma increases HLA-DR synthesis and expression. Basham TY, Merigan TC. J Immunol. 1983; 130 (4): 1492-4
• gamma Interferon production appears to predict time of recurrence of herpes labialis. Cunningham AL, Merigan TC. J Immunol. 1983; 130 (5): 2397-400
• Antiviral treatment of chronic hepatitis B virus infection: infectious virus cannot be detected in patient serum after permanent responses to treatment. Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS. Hepatology. 1982 Jan-Feb; 2 (1): 39-49
• Advances in interferon research - Medical Staff Conference. Creasey AA, Merigan TC. West J Med. 1982; 136 (3): 227-35
• Alpha interferon administration to infants with congenital rubella. Arvin AM, Schmidt NJ, Cantell K, Merigan TC. Antimicrob Agents Chemother. 1982; 21 (2): 259-61
• Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Sacks SL, Scullard GH, Pollard RB, Gregory PB, Robinson WS, Merigan TC. Antimicrob Agents Chemother. 1982; 21 (1): 93-100
• Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. JAMA. 1982; 247 (12): 1718-22
• Cytomegalovirus immune plasma in bone marrow transplant recipients. Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN, Lin CH, Gossett TG, Merigan TC, Gale RP. Ann Intern Med. 1982; 97 (1): 11-8
• Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin. Preiksaitis JK, Rosno S, Rasmussen L, Merigan TC. J Clin Immunol. 1982; 2 (2 Suppl): 36S-41S
• Effects of interferon-alpha on human warts. Pazin GJ, Ho M, Haverkos HW, Armstrong JA, Breinig MC, Wechsler HL, Arvin A, Merigan TC, Cantell K. J Interferon Res. 1982; 2 (2): 235-43
• Human leukocyte interferon for the treatment of varicella in children with cancer. Arvin AM, Kushner JH, Feldman S, Baehner RL, Hammond D, Merigan TC. N Engl J Med. 1982; 306 (13): 761-5
• Immunoregulation by gamma-interferon? Basham T, Merigan TC. Nature. 1982; 299 (5886): 778
• Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy. Sacks SL, Merigan TC, Kaminska J, Fox IH. J Clin Invest. 1982; 69 (1): 226-30
• Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis. Abb J, Deinhardt F, Zander H, Tenser RB, Rapp F, Goust JM, Fudenberg HH, Vilcek J, Ho M, Merigan TC, Oldstone MB, Jackson GG. J Infect Dis. 1982; 146 (1): 109-15
• Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Proc Natl Acad Sci U S A. 1982; 79 (10): 3265-9
• Interferon redux. Friedman RM, Epstein LB, Merigan TC. Nature. 1982; 296 (5859): 704-5
• Interferon-the first quarter century. Merigan TC, JAMA. 1982; 248 (19): 2513-6
• Interferons as antivirals in man. Merigan TC, Philos Trans R Soc Lond B Biol Sci. 1982; 299 (1094): 109-12
• Preliminary studies of acyclovir in chronic hepatitis B. Smith CI, Scullard GH, Gregory PB, Robinson WS, Merigan TC. Am J Med. 1982; 73 (1A): 267-70
• Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Ann Intern Med. 1982; 96 (5): 549-56
• Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. Pollard RB, Arvin AM, Gamberg P, Rand KH, Gallagher JG, Merigan TC. Am J Med. 1982; 73 (5): 679-87
• Systemic antivirals for therapy of herpesvirus diseases. Merigan TC, Dev Biol Stand. 1982: 52 527-33
• Therapeutic approaches to chronic hepatitis B. Smith CI, Merigan TC. Prog Liver Dis. 1982: 7 481-94
• UCLA conference. Interferon: immunobiology and clinical significance. Stiehm ER, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. Ann Intern Med. 1982; 96 (1): 80-93
• Use of intravenous immune globulin in patients receiving bone marrow transplants. Winston DJ, Ho WG, Rasmussen LE, Lin CH, Chu HL, Merigan TC, Gale RP. J Clin Immunol. 1982; 2 (2 Suppl): 42S-47S
• Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. Smith CI, Kitchen LW, Scullard GH, Robinson WS, Gregory PB, Merigan TC. JAMA. 1982; 247 (16): 2261-5
• Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. Rasmussen L, Kelsall D, Nelson R, Carney W, Hirsch M, Winston D, Preiksaitis J, Merigan TC. J Infect Dis. 1982; 145 (2): 191-9
• Dane particle DNA polymerase and HBeAg: impact on clinical, laboratory, and histologic findings in hepatitis B-associated chronic liver disease. Andres LL, Sawhney VK, Scullard GH, Smith JL, Merigan TC, Robinson WS, Gregory PB. Hepatology. 1981 Nov-Dec; 1 (6): 583-5
• Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Scullard GH, Andres LL, Greenberg HB, Smith JL, Sawhney VK, Neal EA, Mahal AS, Popper H, Merigan TC, Robinson WS, Gregory PB. Hepatology. 1981 May-Jun; 1 (3): 228-32
• Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC. J Infect Dis. 1981; 143 (6): 772-83
• Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Chou S, Gallagher JG, Merigan TC. Lancet. 1981; 1 (8235): 1392-4
• Effect of type I and type II interferons on murine thymocyte surface antigen expression: induction or selection? Sonnenfeld G, Meruelo D, McDevitt HO, Merigan TC. Cell Immunol. 1981; 57 (2): 427-39
• Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Gastroenterology. 1981; 81 (6): 987-91
• Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC. Blood. 1981; 58 (4): 712-8
• From the National Institute of Allergy and Infectious Diseases. Report on a workshop on DNA recombinant technology in interferon cloning. Dunnick JK, Merigan TC, Galasso GJ. J Infect Dis. 1981; 143 (2): 297-300
• Human leukocyte interferon treatment of two children with insulin dependent diabetes. Rand KH, Rosenbloom AL, Maclaren NK, Silverstein JH, Riley WJ, Butterworth BE, Yoon JW, Rubenstein AH, Merigan TC. Diabetologia. 1981; 21 (2): 116-9
• Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. Härfast B, Huddlestone JR, Casali P, Merigan TC, Oldstone MB. J Immunol. 1981; 127 (5): 2146-50
• Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer. Merigan TC, Gallagher JG, Pollard RB, Arvin AM. Antimicrob Agents Chemother. 1981; 19 (1): 193-5
• The importance of G0 in the site of action of interferon in the cell cycle. Creasey AA, Bartholomew JC, Merigan TC. Exp Cell Res. 1981; 134 (1): 155-60
• The role of HLA-DR determinants in monocyte-macrophage presentation of herpes simplex virus antigen to human T cells. Stewart GJ, Kelsall BL, Charron DJ, Grumet FC, Merigan TC. Cell Immunol. 1981; 61 (1): 11-21
• Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Engleman EG, Sonnenfeld G, Dauphinee M, Greenspan JS, Talal N, McDevitt HO, Merigan TC. Arthritis Rheum. 1981; 24 (11): 1396-1402
• Virology and immune mechanisms. Merigan TC, Cancer. 1981; 47 (5 Suppl): 1091-4
• Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. J Clin Invest. 1980; 65 (4): 869-78
• Clinical virology, interferon, and infectious diseases in the People's Republic of China in 1979. Merigan TC, J Infect Dis. 1980; 141 (2): 265-70
• Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. Pollard RB, Egbert PR, Gallagher JG, Merigan TC. Ann Intern Med. 1980; 93 (5): 655-64
• Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Egbert PR, Pollard RB, Gallagher JG, Merigan TC. Ann Intern Med. 1980; 93 (5): 664-70
• Does human leukocyte interferon influence the restriction point control in cultured cells? Creasey AA, Bartholomew JC, Merigan TC. Ann N Y Acad Sci. 1980: 350 208-10
• Effect of interferon therapy on circulating lymphocytes in humans. Rasmussen L, Merigan TC. J Interferon Res. 1980; 1 (1): 101-10
• Inhibition of lymphoma hybrids by human interferon. Sikora K, Basham T, Dilley J, Levy R, Merigan T. Lancet. 1980; 2 (8200): 891-3
• Interferon in chronic hepatitis B infection. Merigan TC, Robinson WS, Gregory PB. Lancet. 1980; 1 (8165): 422-3
• Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Creasey AA, Bartholomew JC, Merigan TC. Proc Natl Acad Sci U S A. 1980; 77 (3): 1471-5
• Type I and type II interferons: differential antiviral actions in transformed cells. Bourgeade MF, Chany C, Merigan TC. J Gen Virol. 1980; 46 (2): 449-54
• Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Stevens DA, Merigan TC. Arch Intern Med. 1980; 140 (1): 52-4
• A regulatory role for interferon in immunity. Sonnenfeld G, Merigan TC. Ann N Y Acad Sci. 1979: 332 345-55
• Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses. Hafkin B, Pollard RB, Tiku ML, Robinson WS, Merigan TC. Antimicrob Agents Chemother. 1979; 16 (6): 781-7
• Human interferon as a therapeutic agent. Merigan TC, N Engl J Med. 1979; 300 (1): 42-3
• In vitro production and cellular origin of murine type II interferon. Sonnenfeld G, Mandel AD, Merigan TC. Immunology. 1979; 36 (4): 883-90
• Induction and kinetics of natural killer cells in humans following interferon therapy. Huddlestone JR, Merigan TC, Oldstone MB. Nature. 1979; 282 (5737): 417-9
• Natural killing in estrogen-treated mice responds poorly to poly I.C despite normal stimulation of circulating interferon. Seaman WE, Merigan TC, Talal N. J Immunol. 1979; 123 (6): 2903-5
• Nosocomial varicella. Part I: outbreak in oncology patients at a children's hospital. Meyers JD, MacQuarrie MB, Merigan TC, Jennison MH. West J Med. 1979; 130 (3): 196-9
• Patient factors contributing to the emergence of gentamicin-resistant Serratia marcescens. Yu VL, Oakes CA, Axnick KJ, Merigan TC. Am J Med. 1979; 66 (3): 468-72
• Prolonged herpes-zoster infection associated with immunosuppressive therapy. Gallagher JG, Merigan TC. Ann Intern Med. 1979; 91 (6): 842-6
• Suppressive effect of interferon on erythroid cell proliferation. Ortega JA, Ma A, Shore NA, Dukes PP, Merigan TC. Exp Hematol. 1979; 7 (3): 145-50
• Toxicity of vidarabine. Sacks SL, Smith JL, Pollard RB, Sawhney V, Mahol AS, Gregory P, Merigan TC, Robinson WS. JAMA. 1979; 241 (1): 28-9
• Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. Pollard RB, Rand KH, Arvin AM, Merigan TC. J Infect Dis. 1978; 137 (5): 541-9
• Cytomegalovirus: a not so innocent bystander. Rand KH, Merigan TC. JAMA. 1978; 240 (22): 2470-1
• Effect of vidarabine on chronic hepatitis B virus infection. Pollard RB, Smith JL, Neal A, Gregory PB, Merigan TC, Robinson WS. JAMA. 1978; 239 (16): 1648-50
• Factors affecting the interferon sensitivity of human cytomegalovirus. Holmes AR, Rasmussen L, Merigan TC. Intervirology. 1978; 9 (1): 48-55
• Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP. N Engl J Med. 1978; 298 (18): 981-7
• Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Arvin AM, Feldman S, Merigan TC. Antimicrob Agents Chemother. 1978; 13 (4): 605-7
• Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. Rand KH, Pollard RB, Merigan TC. N Engl J Med. 1978; 298 (17): 951-3
• Lymphocyte transformation and interferon production as measures of cellular immunity in lymphoma patients. Arvin AM, Pollard RB, Rasmussen LE, Rand KH, Merigan TC. IARC Sci Publ. 1978; (24 Pt 2): 745-51
• Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients. Pollard RB, Merigan TC. Transplant Proc. 1978; 10 (1): 241-5
• Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA. N Engl J Med. 1978; 299 (26): 1449-53
• Prospects for control of herpesvirus-related diseases: a review. Merigan TC, Rand KH. IARC Sci Publ. 1978; (24 Pt 2): 947-63
• Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Rasmussen L, Merigan TC. Proc Natl Acad Sci U S A. 1978; 75 (8): 3957-61
• Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. J Infect Dis. 1978; 137 (5): 531-40
• Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Sonnenfeld G, Mandel AD, Merigan TC. Cell Immunol. 1978; 40 (2): 285-93
• Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Rand KH, Johnson KP, Rubinstein LJ, Wolinsky JS, Penney JB, Walker DL, Padgett BL, Merigan TC. Ann Neurol. 1977; 1 (5): 458-62
• Can immunization eradicate viral diseases. Rand KH, Merigan TC. Arch Intern Med. 1977; 137 (6): 723-4
• Cellular immunity and herpesvirus infections in cardiac-transplant patients. Rand KH, Rasmussen LE, Pollard RB, Arvin A, Merigan TC. N Engl J Med. 1977; 296 (24): 1372-7
• Inhibition of multiplication of Mycobacterium leprae by polyinosinic-polycytidylic acid. Levy L, Merigan TC. Antimicrob Agents Chemother. 1977; 11 (1): 122-5
• Interferon inhibition of lymphocyte mitogenesis. Weinstein Y, Brodeur BR, Melmon KL, Merigan TC. Immunology. 1977; 33 (3): 313-9
• Interferon production during lymphocytic choriomeningitis virus infection of nude and normal mice. Merigan TC, Oldstone MB, Welsh RM. Nature. 1977; 268 (5615): 67-8
• Multiplicity-dependent replication of varicella-zoster virus in interferon-treated cells. Rasmussen L, Holmes AR, Hofmeister B, Merigan TC. J Gen Virol. 1977; 35 (2): 361-8
• Pharmacokinetics and side effects of interferon in man. Merigan TC, Tex Rep Biol Med. 1977: 35 541-7
• Reciprocal changes in interferon production and immune responses of mouse spleen cells fractionated over columns of insolubilized conjugates of histamine. Brodeur BR, Weinstein Y, Melmon KL, Merigan TC. Cell Immunol. 1977; 29 (2): 363-72
• The immunosuppressive effect of type II mouse interferon preparations on antibody production. Sonnenfeld G, Mandel AD, Merigan TC. Cell Immunol. 1977; 34 (2): 193-206
• Cellular immunity to herpes simplex infection in humans. Rasmussen L, Haahr S, Merigan TC. Surv Ophthalmol. 1976 Sep-Oct; 21 (2): 191-3
• Virus infections. Stevens DA, Merigan TC. Int J Radiat Oncol Biol Phys. 1976 Jan-Feb; 1 (3-4): 317-20
• Antivirals with clinical potential. Introduction. Merigan TC, J Infect Dis. 1976: 133 Suppl A1-2
• Diagnosis of cytomegalovirus pneumonia in compromised hosts. Abdallah PS, Mark JB, Merigan TC. Am J Med. 1976; 61 (3): 326-32
• Editorial: Efficacy of adenine arabinoside in herpes zoster. Merigan TC, N Engl J Med. 1976; 294 (22): 1233-4
• Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. N Engl J Med. 1976; 295 (10): 517-22
• Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. Arvin AM, Yeager AS, Merigan TC. J Infect Dis. 1976: 133 Suppl A205-10
• Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Haahr S, Rasmussen L, Merigan TC. Infect Immun. 1976; 14 (1): 47-54
• Measles in adults. An unforeseen consequence of immunization? Rand KH, Emmons RW, Merigan TC. JAMA. 1976; 236 (9): 1028-31
• Nosocomial vaccinia infection. Johnson RH, Krupp JR, Hoffman AR, Koplan JP, Nakano JH, Merigan TC. West J Med. 1976; 125 (4): 266-70
• Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients. Wolinsky JS, Johnson KP, Rand K, Merigan TC. Trans Am Neurol Assoc. 1976: 101 81-2
• Role of interferon in prophylaxis of rabies after exposure. Wiktor TJ, Koprowski H, Mitchell JR, Merigan TC. J Infect Dis. 1976: 133 Suppl A260-5
• 'Non-specific' mediators in host defense against respiratory viruses: assay methods and results. Merigan TC, Dev Biol Stand. 1975: 28 211-23
• Cellular events in zoster vesicles: relation to clinical course and immune parameters. Stevens DA, Ferrington RA, Jordan GW, Merigan TC. J Infect Dis. 1975; 131 (5): 509-15
• Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. Valle MJ, Jordan GW, Haahr S, Merigan TC. J Immunol. 1975; 115 (1): 230-3
• Enhancement of host defense mechanisms by pharmacological agents. Jordan GW, Merigan TC. Annu Rev Pharmacol. 1975: 15 157-75
• Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. Valle MJ, Bobrove AM, Strober S, Merigan TC. J Immunol. 1975; 114 (1 Pt 2): 435-41
• Mechanism of the suppressive effect of interferon on antibody synthesis in vivo. Brodeur BR, Merigan TC. J Immunol. 1975; 114 (4): 1323-8
• Randomized trial of transfer factor treatment of human warts. Stevens DA, Ferrington RA, Merigan TC, Marinkovich VA. Clin Exp Immunol. 1975; 21 (3): 520-4
• The lact of antiviral effect of (polyinosinic acid): (polycytidylic acid) when attached to insoluble supports. Hutchinson DW, Merigan TC. J Gen Virol. 1975; 27 (3): 403-7
• Interferon: its inducers and some aspects of host resistance in malignancy. Merigan TC, Cancer Chemother Rep. 1974 Jul-Aug; 58 (4): 571-8
• Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection. Jordan GW, Fried RP, Merigan TC. J Infect Dis. 1974; 130 (1): 56-62
• Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. Jordan GW, Merigan TC. J Infect Dis. 1974; 130 (5): 495-501
• Clinical testing of human interferon in infectious diseases. Merigan TC, In Vitro Monogr. 1974; (3): 57-62
• Host defenses against viral disease. Merigan TC, N Engl J Med. 1974; 290 (6): 323-9
• Influence of increasing 2'-O-methylation on the interferon stimulating capacity of poly(rl)-poly(rC). Merigan TC, Rottman F. Virology. 1974; 60 (1): 297-301
• Interferon production by individual cells. Rodgers R, Merigan TC. Virology. 1974; 57 (2): 467-74
• Lymphocyte interferon production and transformation after Herpes simplex infections in humans. Rasmussen LE, Jordan GW, Stevens DA, Merigan TC. J Immunol. 1974; 112 (2): 728-36
• Quantitative aspects of interferon-induced plaque reduction: effects of cell age and dose of challenge virus. Jordan GW, Merigan TC. Proc Soc Exp Biol Med. 1974; 145 (3): 1037-41
• Replication or inactivation of different viruses by human lymphocyte preparations. Denman AM, Rager-Zisman B, Merigan TC, Tyrrell DA. Infect Immun. 1974; 9 (2): 373-6
• Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. Brodeur BR, Merigan TC. J Immunol. 1974; 113 (4): 1319-25
• A useful quantitative semimicromethod for viral plaque assay. Rager-Zisman B, Merigan TC. Proc Soc Exp Biol Med. 1973; 142 (4): 1174-9
• Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. Stevens DA, Jordan GW, Waddell TF, Merigan TC. N Engl J Med. 1973; 289 (17): 873-8
• An artificial intelligence program to advise physicians regarding antimicrobial therapy. Shortliffe EH, Axline SG, Buchanan BG, Merigan TC, Cohen SN. Comput Biomed Res. 1973; 6 (6): 544-60
• Herpes zoster: recent studies. Stevens DA, Merigan TC. Natl Cancer Inst Monogr. 1973: 36 465-8
• Inhibition of respiratory virus infection by locally applied interferon. Merigan TC, Reed SE, Hall TS, Tyrrell DA. Lancet. 1973; 1 (7803): 563-7
• Structure and infectivity of picornaviral RNA encapsidated by cowpea chlorotic mottle virus protein. Black DR, Connell CJ, Merigan TC. J Virol. 1973; 12 (6): 1209-15
• Studies on the toxicity and antiviral activity of various polynucleotides. Black DR, Eckstein F, DeClercq E, Merigan TC. Antimicrob Agents Chemother. 1973; 3 (2): 198-206
• Suppression of mouse antibody producing spleen cells by various interferon preparations. Chester TJ, Paucker K, Merigan TC. Nature. 1973; 246 (5428): 92-4
• The effect of bursectomy and thymectomy on the course of avian influenza virus infection. Portnoy J, Bloom K, Merigan TC. Cell Immunol. 1973; 9 (2): 251-62
• Cat interferon inhibits feline leukaemia virus infection in cell culture. Rogers R, Merigan TC, Hardy WD, Old LJ, Kassel R. Nat New Biol. 1972; 237 (78): 270-1
• Herpes Zoster-Varicella infections and lymphoma. Goffinet DR, Glatstein EJ, Merigan TC. Ann Intern Med. 1972; 76 (2): 235-40
• In vivo release of previously cleared interferon by cycloheximide. Chester TJ, De Clercq E, Nuwer MR, Merigan TC. Infect Immun. 1972; 5 (3): 383-8
• Interferon and its inducers: antiviral and other effects. Rodgers R, Merigan TC. CRC Crit Rev Clin Lab Sci. 1972; 3 (2): 131-62
• Interferon, antibody, and other host factors in herpes zoster. Stevens DA, Merigan TC. J Clin Invest. 1972; 51 (5): 1170-8
• Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Epstein LB, Stevens DA, Merigan TC. Proc Natl Acad Sci U S A. 1972; 69 (9): 2632-6
• Studies on the antiviral activity and cell interaction of synthetic double-stranded polyribo- and polydeoxyribonucleotides. De Clercq E, Wells RD, Merigan TC. Virology. 1972; 47 (2): 405-15
• The antiviral activity of certain thiophosphate and 2'-chloro substituted polynucleotide homopolymer duplexes. Black DR, Eckstein F, Hobbs JB, Sternbach H, Merigan TC. Virology. 1972; 48 (2): 537-45
• Uncertain role of cytosine arabinoside in varicella infection of compromised hosts. Stevens DA, Merigan TC. J Pediatr. 1972; 81 (3): 562-5
• [Evaluation of teleroentgenography in the surgical and orthodontical treatment of prognathism]. Black DR, Eckstein F, Hobbs JB, Sternbach H, Merigan TC. Fogorv Sz. 1972; 65 (5): 138-44
• Viral infections in man associated with acquired immunological deficiency states. Merigan TC, Stevens DA. Fed Proc. 1971 Nov-Dec; 30 (6): 1858-64
• Approach to diagnosis and treatment of herpes simplex encephalitis. A report of two cases. Gurwith MJ, Harman CE, Merigan TC. Calif Med. 1971; 115 (6): 63-71
• Approaches to the control of viral infections in man. Stevens DA, Merigan TC. Ration Drug Ther. 1971; 5 (9): 1-5
• Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. De Clercq E, Merigan TC. J Infect Dis. 1971; 123 (2): 190-9
• Effect of Separate and Combined Injections of Poly rI: Poly rC and Endotoxin on Reticulo-endothelial Activity, Interferon, and Antibody Production in the Mouse. Chester TJ, de Clercq E, Merigan TC. Infect Immun. 1971; 3 (4): 516-20
• Hemolytic-uremic-like syndrome following polycarboxylate interferon induction. Treatment of Dawson's inclusion-body encephalitis. Leavitt TJ, Merigan TC, Freeman JM. Am J Dis Child. 1971; 121 (1): 43-7
• Inhibition of radiogenic lymphoma development in mice by interferon. Lieberman M, Merigan TC, Kaplan HS. Proc Soc Exp Biol Med. 1971; 138 (2): 575-8
• Inhibition of rubella virus-specific RNA synthesis by interferon. Wong KT, Robinson WS, Merigan TC. Proc Soc Exp Biol Med. 1971; 136 (2): 615-8
• Interferon clearance rate decreased after repeated injections. Nuwer MR, De Clercq E, Merigan TC. J Gen Virol. 1971; 12 (2): 191-4
• PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Epstein LB, Cline MJ, Merigan TC. Cell Immunol. 1971; 2 (6): 602-13
• Septicemia with Pasteurella pseudotuberculosis and liver disease. Marlon A, Gentry L, Merigan TC. Arch Intern Med. 1971; 127 (5): 947-9
• The effect of interferon and interferon inducers on avian influenza. Portnoy J, Merigan TC. J Infect Dis. 1971; 124 (6): 545-52
• The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. Epstein LB, Cline MJ, Merigan TC. J Clin Invest. 1971; 50 (4): 744-53
• Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides. De Clercq E, Wells RD, Grant RC, Merigan TC. J Mol Biol. 1971; 56 (1): 83-100
• Varicella zoster virus: interferon production and comparative interferon sensitivity in human cell cultures. Armstrong RW, Merigan TC. J Gen Virol. 1971; 12 (1): 53-4
• Current concepts of interferon and interferon induction. De Clercq E, Merigan TC. Annu Rev Med. 1970: 21 17-46
• Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. Armstrong RW, Gurwith MJ, Waddell D, Merigan TC. N Engl J Med. 1970; 283 (22): 1182-7
• Effect of interferon on the replication of Sendai virus. Richman DD, Wong KT, Robinson WS, Merigan TC. J Gen Virol. 1970; 9 (2): 141-50
• Failure of an interferon inducer to inhibit multiplication of Mycobacterium leprae. Levy L, Merigan TC. Proc Soc Exp Biol Med. 1970; 134 (1): 87-9
• Increase in antiviral activity of polynucleotides by thermal activation. De Clercq E, Wells RD, Merigan TC. Nature. 1970; 226 (5243): 364-6
• Induction of interferon by nonviral agents. De Clercq E, Merigan TC. Arch Intern Med. 1970; 126 (1): 94-108
• Interferon stimulated by double stranded RNA. Merigan TC, Nature. 1970; 228 (5268): 219-22
• Nonviral interferon inducers. Merigan TC, De Clercq E, Bausek GH. J Gen Physiol. 1970; 56 (1): 57-75
• On-line computer quality control of antibiotic-sensitivity testing. Petralli J, Russell E, Kataoka A, Merigan TC. N Engl J Med. 1970; 283 (14): 735-8
• Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI*Poly rC. De Clercq E, Nuwer MR, Merigan TC. Infect Immun. 1970; 2 (1): 69-76
• Simultaneous viral and non-viral interferon production in human cell cultures. Bausek GH, Merigan TC. Proc Soc Exp Biol Med. 1970; 133 (3): 982-5
• Stimulation or inhibition of interferon production depending on time of cycloheximide administration. De Clercq E, Merigan TC. Virology. 1970; 42 (3): 799-802
• Symposium on interferon and host response to virus infection. Introduction. Merigan TC, Arch Intern Med. 1970; 126 (1): 49-50
• Synthetic polyanions protect mice against intracellular bacterial infection. Remington JS, Merigan TC. Nature. 1970; 226 (5243): 361-3
• The antiviral activity of thiophosphate-substituted polyribonucleotides in vitro and in vivo. CDe Clercq E, Eckstein F, Sternbach H, Merigan TC. Virology. 1970; 42 (2): 421-8
• The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. De Clercq E, Nuwer MR, Merigan TC. J Clin Invest. 1970; 49 (8): 1565-77
• Two mechanisms of cell resistance to repeated stimulation of interferon. Bausek GH, Merigan TC. Proc Soc Exp Biol Med. 1970; 134 (3): 672-6
• An active interferon inducer obtained from Hemophilus influenzae type B. De Clercq E, Merigan TC. J Immunol. 1969; 103 (5): 899-906
• Cell interaction with a synthetic polynucleotide and interferon production in vitro. Bausek GH, Merigan TC. Virology. 1969; 39 (3): 491-8
• Effect of interferon on the course of spontaneous and radiation-induced renal lesions in the RF-Un mouse. Guttman PH, Davis WC, Fudenberg HH, Merigan TC. Vox Sang. 1969; 17 (4): 279-88
• Interferon induction by and ribonuclease sensitivity of thiophosphate-substituted polyribonucleotides. De Clercq E, Eckstein F, Sternbach H, Merigan TC. Antimicrob Agents Chemother (Bethesda). 1969: 9 187-91
• Management of infected cardiac valve prostheses. Walker SR, Shumway NE, Merigan TC. JAMA. 1969; 208 (3): 531-3
• Requirement of a stable secondary structure for the antiviral activity of polynucleotides. De Clercq E, Merigan TC. Nature. 1969; 222 (5199): 1148-52
• Resistance to virus challenge in mice infected with protozoa or bacteria. Remington JS, Merigan TC. Proc Soc Exp Biol Med. 1969; 131 (4): 1184-8
• Successful renal allograft in a patient with pulmonary cryptococcus. Swenson RS, Kountz SL, Blank N, Merigan TC. Arch Intern Med. 1969; 124 (4): 502-6
• Synthesis of viral-specific ribonucleic Acid in rubella virus-infected cells. Wong KT, Robinson WS, Merigan TC. J Virol. 1969; 4 (6): 901-3
• [Interferon induction increased through chemical modification of a synthetic polyribonucleotide]. De Clercq E, Eckstein E, Merigan TC. Science. 1969; 165 (3898): 1137-9
• Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Finkelstein MS, Bausek GH, Merigan TC. Science. 1968; 161 (3840): 465-8
• Interferon production in human mumps infections. Waddell DJ, Wilbur JR, Merigan TC. Proc Soc Exp Biol Med. 1968; 127 (1): 320-4
• Interferon--1968. How much do we understand? Finkelstein MS, Merigan TC. Calif Med. 1968; 109 (1): 24-34
• Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Merigan TC, Finkelstein MS. Virology. 1968; 35 (3): 363-74
• Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Remington JS, Merigan TC. Science. 1968; 161 (3843): 804-6
• Modified skin lesions during concurrent varicella and measles infections. Merigan TC, Waddell D, Grossman M, Ritchie JH, Mo G. JAMA. 1968; 204 (4): 333-5
• Molecular species of circulating interferon in mice injected with Newcastle disease virus. Hallum JV, Youngner JS, Merigan TC. Virology. 1968; 34 (4): 802-4
• Action of isoproterenol on heart cells in tissue culture. Harrison DC, Kleiger RE, Merigan TC. Proc Soc Exp Biol Med. 1967; 124 (1): 122-6
• Effect of interferon on TRIC agents and induction of interferon by TRIC agents. Hanna L, Merigan TC, Jawetz E. Am J Ophthalmol. 1967; 63 (5): Suppl:1115-9
• Induction of circulating interferon by synthetic anionic polymers of known composition. Merigan TC, Nature. 1967; 214 (5086): 416-7
• Interferon and cytomegalovirus in vivo and in vitro. Glasgow LA, Hanshaw JB, Merigan TC, Petralli JK. Proc Soc Exp Biol Med. 1967; 125 (3): 843-9
• Interferon induction in man by a synthetic polyanion of defined composition. Merigan TC, Regelson W. N Engl J Med. 1967; 277 (24): 1283-7
• Interferon's promise in clinical medicine. Fact or fancy? Merigan TC, Am J Med. 1967; 43 (6): 817-21
• Interferons of mice and men. Merigan TC, N Engl J Med. 1967; 276 (16): 913-20
• Sequoiosis. A granulomatous pneumonitis associated with redwood sawdust inhalation. Cohen HI, Merigan TC, Kosek JC, Eldridge F. Am J Med. 1967; 43 (5): 785-94
• Various molecular species of interferon induced by viral and nonviral agents. Merigan TC, Bacteriol Rev. 1967; 31 (2): 138-44
• A second molecular species of mouse interferon in mice injected with statolon. Merigan TC, Kleinschmidt WJ. Nature. 1966; 212 (5068): 1383-4
• Characteristics of interferon induced in vitro and in vivo by a TRIC agent. Merigan TC, Hanna L. Proc Soc Exp Biol Med. 1966; 122 (2): 421-4
• Concerning the mechanism of action of interferon. Joklik WK, Merigan TC. Proc Natl Acad Sci U S A. 1966; 56 (2): 558-65
• Effect of crude and purified interferons on the gowth of uninfected cells in culture. Baron S, Merigan TC, McKerlie ML. Proc Soc Exp Biol Med. 1966; 121 (1): 50-2
• Hereditary occurrence of cystic disease of the renal medulla. Goldman SH, Walker SR, Merigan TC, Gardner KD, Bull JM. N Engl J Med. 1966; 274 (18): 984-92
• Heterogeneity of rabbit serum interferons. Ke YH, Ho M, Merigan TC. Nature. 1966; 211 (5048): 541-2
• In vitro and in vivo antiviral action of an interferon-like substance induced by Toxoplasma gondii. Freshman MM, Merigan TC, Remington JS, Brownlee IE. Proc Soc Exp Biol Med. 1966; 123 (3): 862-6
• Inhibition of TRIC agents by virus-induced interferon. Hanna L, Merigan TC, Jawetz E. Proc Soc Exp Biol Med. 1966; 122 (2): 417-21
• Interferon and uninfected cells. Levy HB, Merigan TC. Proc Soc Exp Biol Med. 1966; 121 (1): 53-5
• Physical properties of human interferon prepared in vitro and in vivo. Merigan TC, Gregory DF, Petralli JK. Virology. 1966; 29 (4): 515-22
• The essential role of specific conformation in the antigenicity of ribonuclease. Merigan TC, Potts JT. Biochemistry. 1966; 5 (3): 910-6
• Variation in adrenal cortical hormones within physiologic ranges, stress and interferon production in mice. Solomon GF, Merigan TC, Levine S. Riv Patol Nerv Ment. 1966; 87 (4): 74-9
• ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. PETRALLI JK, MERIGAN TC, WILBUR JR. Lancet. 1965; 2 (7409): 401-5
• CIRCULATING INTERFERON AFTER MEASLES VACCINATION. PETRALLI JK, MERIGAN TC, WILBUR JR. N Engl J Med. 1965: 273 198-201
• PURIFIED INTERFERONS: PHYSICAL PROPERTIES AND SPECIES SPECIFICITY. MERIGAN TC, Science. 1964; 145 (3634): 811-3
• Studies on the antigenic combining sites in bacteriophage lysozyme. MERIGAN TC, DREYER WJ. Ann N Y Acad Sci. 1963: 103 765-72
• Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices. A controlled evaluation. MERIGAN TC, PLOTKIN GR, DAVIDSON CS. N Engl J Med. 1962: 266 134-5
• Plasma fibrinolysis in man: the effect of chylomicrons derived from different dietary fats. FARQUHAR JW, MERIGAN TC, SOKOLOW M. J Exp Med. 1961: 113 587-97
• Treatment of hypercalcemia in multiple myeloma. Report of two patients. MERIGAN TC, HAYES RE. Arch Intern Med. 1961: 107 389-94
• Gastrointestinal bleeding with cirrhosis. A study of 172 episodes in 158 patients. MERIGAN TC, HOLLISTER RM, GRYSKA PF, STARKEY GW, DAVIDSON CS. N Engl J Med. 1960: 263 579-85
• Retrobulbar hemorrhage in a hemophiliac with irreversible loss of vision. ZIMMERMAN A, MERIGAN TC. Arch Ophthalmol. 1960: 64 949-50
• Thalassemia major. Thirty-five year survival, with obliterative pulmonary endarteritis and atypical bone changes. COVEY MC, MERIGAN TC, PETRAKIS NL, LUCIA SP. Am J Med. 1960: 28 482-6
• Effect of chylomicrons on the fibrinolytic activity of normal human plasma in vitro. MERIGAN TC, FARQUHAR JW, WILLIAMS JH, SOKOLOW M. Circ Res. 1959; 7 (2): 205-9